Matthew Del Giudice
Net worth: 16 000 $ as of 30/06/2026
Net worth: 16 000 $ as of 30/06/2026
Matthew Paul Del Giudice is currently an Independent Director at MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc., both positions starting in 2024.
Formerly, the role was Head-General Overnight Emergency Radiologist at The Cleveland Clinic Foundation from 2021 to 2022.
Education includes undergraduate studies at the University of Illinois At Urbana–Champaign and a doctorate from Stritch School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/05/2026 | 12,500 ( 0.04% ) | 16 000 $ | 30/06/2026 | |
| 12/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
| Companies | Position | Start |
|---|---|---|
| MIRA PHARMACEUTICALS, INC. | Director/Board Member | 13/03/2024 |
| TELOMIR PHARMACEUTICALS, INC. | Director/Board Member | 12/08/2024 |
| Companies | Position | End |
|---|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Corporate Officer/Principal | 01/05/2022 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
The Cleveland Clinic Foundation
The Cleveland Clinic Foundation Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Stritch School of Medicine
Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. Pharmaceuticals: OtherHealth Technology Develops and sells new molecular synthetic THC for the treatment of adult patients with anxiety and cognitive decline | Health Technology |
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops a novel small molecule as the first regulator of telomere length and genomic stability | Health Technology |
Select your edition
All financial news and data tailored to specific country editions